Paola Trono

Research Area: Molecular Oncology

Monterotondo Scalo – Campus “A.Buzzati Traverso”


  • 2007: PhD in Experimental Physiopathology, University “Tor Vergata”, Rome.
  • 2004: Specialist in Biotechnological Applications, University of Bari.
  • 2001: Biological Sciences Doctoral Degree, University of Bari. 


  • Current position: Permanent Researcher position at Institute of Biochemistry and Cell Biology (IBBC), National Research Council of Italy (CNR), Rome, Italy.January 2020-June 2020: Researcher at Tumor Immunology and Immunotherapy Unit, Regina Elena National Tumor Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
  • 2008-2019: Researcher Fellow, Tumor Immunology and Immunotherapy Unit, Regina Elena National Tumor Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
  • 2007-2008: Postdoctoral Fellow, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • 2003-2006: Doctoral Internship, Department of Experimental Medicine and Biochemical Science, University “Tor Vergata”, Rome, Italy.
  • 2000-2003: Pre-Doctoral Internship, Department of Biochemistry and Molecular Biology, University of Bari. 


2007-2008: Postdoctoral research fellowship. National Institutes of Health, Fogarty International Center Bethesda, USA.

  • Trono P, Tocci A, Musella M, Sistigu A, Nisticò P. “Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?” Biology (Basel). 2021 Sep 14;10(9):913. DOI: 10.3390/biology10090913.
  • Melchionna R*, Trono P*, Tocci A, Nisticò P. “Actin Cytoskeleton and Regulation of TGFβ Signaling: Exploring Their Links” Biomolecules. 2021 Feb 23;11(2):336. DOI: 10.3390/biom11020336
  • Di Modugno F, Colosi C, Trono P, Antonacci G, Ruocco G, Nisticò P. “3D models in the new era of immune oncology: focus on T cells, CAF and ECM” Journal of Experimental Clinical and Cancer Research, 2019, 38:117; DOI: 10.1186/s13046-019-1086-2.
  • Trono P, Sistigu A, Palermo B, Ciliberto G, Nisticò P. “Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to Immune Checkpoint Blockers” Emerging Topics in Life Sciences, Dec 12, 2017, 1 (5) 471-486; DOI: 10.1042/ETLS20170068.
  • Melchionna R, Iapicca P, Di Modugno F, Trono P, Sperduti I,  Fassan M, Cataldo I, Rusev BC, Lawlor RT,  Diodoro MG, Milella M, Grazi GL, Bissell MJ, Scarpa A and Nisticò P. “The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome” Oncoimmunology 2016; 5:12, e1221556, DOI: 10.1080/2162402X.2016.1221556.
  • Trono P, Di Modugno F, Circo R, Spada S, Melchionna R, Palermo B, Matteoni S, Soddu S, De Maria R. and Nisticò P. ″hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells″ Oncogene 2016 Feb 18;35(7):887-96.
  • Trono P, Di Modugno F, Nisticò P. “hMENA11a, a hMENA isoform sending survival signals” Mol Cell Oncol. 2015 Aug 27;3(2):e1083648. doi: 10.1080/23723556.2015.1083648.
  • Di Modugno F, Mottolese M, DeMonte L, Trono P, Balsamo M, Conidi A, Melucci E, Terrenato I, Belleudi F, Torrisi MR, Alessio M, Santoni A, Nisticò P. “The cooperation between hMena overexpression and HER2 signalling in breast cancer” Plos One 2010 Dec; 5 (12)
  • Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. “The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cell” J Clin Invest. 2010 Feb; 120 (2): 533-44.